AMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Quarterly Sales of $168.28 Million
Equities research analysts expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will announce sales of $168.28 million for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for AMAG Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $161.86 million and the highest estimate coming in at $173.62 million. AMAG Pharmaceuticals reported sales of $143.78 million during the same quarter last year, which would suggest a positive year over year growth rate of 17%. The business is expected to report its next quarterly earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full year sales of $168.28 million for the current financial year, with estimates ranging from $638.99 million to $658.20 million. For the next financial year, analysts forecast that the business will report sales of $544.74 million per share, with estimates ranging from $481.01 million to $584.07 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. During the same period in the previous year, the company earned $1.45 EPS. The company’s revenue for the quarter was up 24.3% on a year-over-year basis.
A number of research firms have recently issued reports on AMAG. Barclays PLC reaffirmed a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. ValuEngine raised AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. TheStreet cut AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 5th. Citigroup Inc. cut their price objective on AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a research report on Friday, July 7th. Finally, Jefferies Group LLC set a $40.00 price objective on AMAG Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, April 20th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $28.09.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/11/amag-pharmaceuticals-inc-amag-expected-to-post-quarterly-sales-of-168-28-million.html.
In related news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the sale, the senior vice president now owns 28,336 shares of the company’s stock, valued at approximately $566,720. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.80% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue increased its position in shares of AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 3,081 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 510 shares in the last quarter. Advisors Asset Management Inc. increased its position in shares of AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 5,005 shares in the last quarter. Mason Street Advisors LLC increased its position in shares of AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after buying an additional 554 shares in the last quarter. Finally, Sei Investments Co. increased its position in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 54 shares in the last quarter.
AMAG Pharmaceuticals (NASDAQ AMAG) traded up 2.09% during midday trading on Friday, reaching $17.10. The company had a trading volume of 1,028,289 shares. The company’s 50-day moving average is $19.09 and its 200 day moving average is $20.86. The company’s market cap is $603.42 million. AMAG Pharmaceuticals has a 52-week low of $16.00 and a 52-week high of $36.83.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.